Floatz logo

Tivantinib

Nonsquamous Nonsmall Cell Neoplasm of Lung

Armando Santoro, MDSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nonsquamous Nonsmall Cell Neoplasm of Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Arcus Biosciences, Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Intergroupe Francophone de Cancerologie Thoracique
Phase 2BB
(+)-VINCRISTINE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Irinotecan
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Demcizumab
OncoMed Pharmaceuticals, Inc.
Phase 2B

View all 20 →

Same molecule, other indications

Tivantinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →